Last reviewed · How we verify
Intravenous (IV) infusions
IV infusions are a delivery route for pharmaceutical agents administered directly into the bloodstream.
At a glance
| Generic name | Intravenous (IV) infusions |
|---|---|
| Sponsor | Polpharma Biologics S.A. |
| Modality | Biologic |
| Phase | Phase 3 |
Mechanism of action
Intravenous infusion is a method of drug administration rather than a specific drug mechanism. It allows direct delivery of therapeutic agents into the venous system, bypassing first-pass metabolism and enabling rapid systemic distribution. The actual mechanism depends on the specific drug being infused.
Approved indications
Common side effects
Key clinical trials
- A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) (PHASE1)
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (PHASE2)
- AAV8-hCocH for Cocaine Use Disorder (PHASE1)
- A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies (PHASE2)
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) (PHASE2, PHASE3)
- A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) (PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous (IV) infusions CI brief — competitive landscape report
- Intravenous (IV) infusions updates RSS · CI watch RSS
- Polpharma Biologics S.A. portfolio CI